Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

COVID-19 2Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × cilgavimab and tixagevimab drug combination × Clear all
NCT05465876 2024-04-04

PACE-CLL

Sunnybrook Health Sciences Centre

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡